1. Home
  2. ALT vs GEVO Comparison

ALT vs GEVO Comparison

Compare ALT & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • GEVO
  • Stock Information
  • Founded
  • ALT 1997
  • GEVO 2005
  • Country
  • ALT United States
  • GEVO United States
  • Employees
  • ALT N/A
  • GEVO N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • GEVO Major Chemicals
  • Sector
  • ALT Health Care
  • GEVO Industrials
  • Exchange
  • ALT Nasdaq
  • GEVO Nasdaq
  • Market Cap
  • ALT 292.0M
  • GEVO 418.4M
  • IPO Year
  • ALT N/A
  • GEVO 2011
  • Fundamental
  • Price
  • ALT $3.83
  • GEVO $1.73
  • Analyst Decision
  • ALT Strong Buy
  • GEVO Buy
  • Analyst Count
  • ALT 6
  • GEVO 2
  • Target Price
  • ALT $17.40
  • GEVO $7.58
  • AVG Volume (30 Days)
  • ALT 3.0M
  • GEVO 9.4M
  • Earning Date
  • ALT 08-12-2025
  • GEVO 08-11-2025
  • Dividend Yield
  • ALT N/A
  • GEVO N/A
  • EPS Growth
  • ALT N/A
  • GEVO N/A
  • EPS
  • ALT N/A
  • GEVO N/A
  • Revenue
  • ALT $20,000.00
  • GEVO $80,187,000.00
  • Revenue This Year
  • ALT N/A
  • GEVO $909.99
  • Revenue Next Year
  • ALT $761,880.20
  • GEVO $22.37
  • P/E Ratio
  • ALT N/A
  • GEVO N/A
  • Revenue Growth
  • ALT N/A
  • GEVO 341.75
  • 52 Week Low
  • ALT $2.90
  • GEVO $0.67
  • 52 Week High
  • ALT $11.16
  • GEVO $3.39
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • GEVO 57.77
  • Support Level
  • ALT $3.35
  • GEVO $1.54
  • Resistance Level
  • ALT $3.66
  • GEVO $1.86
  • Average True Range (ATR)
  • ALT 0.19
  • GEVO 0.14
  • MACD
  • ALT 0.07
  • GEVO 0.01
  • Stochastic Oscillator
  • ALT 86.18
  • GEVO 31.15

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About GEVO Gevo Inc.

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.

Share on Social Networks: